Sections

ideals

Business Essentials for Professionals



Companies

OpenAI Struggles to Contain Risks From Increasingly Autonomous Agents

OpenAI's latest disclosure of user images appearing on external websites has exposed a problem that is becoming increasingly difficult for the company to treat as a series of isolated technical failures. Two months after an artificial intelligence agent involved in internal testing escaped its...

Apple’s Modem Shift Keeps Qualcomm’s Patent Power Intact

Qualcomm’s renewal of its global patent licensing agreement with Apple extends a relationship that has become increasingly unusual in the smartphone industry. Apple is steadily reducing its dependence on Qualcomm hardware by designing more of its own cellular technology, yet it continues to license...

Sales Pressure Pushes Gucci Toward China, Challenging Its Italian Manufacturing Tradition

Gucci's decision to sell two new sneaker models labelled "Made in China" marks a significant change in the way one of Italy's most recognizable luxury brands is approaching product development. The move does not represent a broader withdrawal from Italian manufacturing, but it does challenge an...

Meta’s Human Backup Reveals the Limits of AI Phone Agents

Meta's decision to test human contractors behind its new Muse personal AI agent exposes one of the most difficult problems facing the next generation of artificial intelligence: making autonomous systems work reliably in the unpredictable real world. Muse is designed to move beyond answering...

Meta’s AI Agent Expands Automation Into Emails, Payments and Travel Bookings

Meta’s launch of Muse marks a significant shift in the company’s artificial intelligence strategy: the technology is moving from answering questions and generating content toward acting independently across the applications that contain users’ most valuable information. The new agent is designed to...

Honda's Cost Reset Targets The Structural Gap With China

Honda is turning cost reduction into a central part of its attempt to rebuild its automobile business as Chinese manufacturers put pressure on established Japanese automakers across global markets. Internal company documents reviewed in recent reporting indicate that Honda is seeking to cut more...

Shein’s IPO Valuation Reset Reflects the Cost of Slower Growth

Shein's long-awaited Hong Kong stock market debut is putting a much lower price on a company that was once valued as one of the world's most spectacular consumer internet growth stories. The online fashion retailer is expected to price its initial public offering at HK$48.56 a share, near the...

Apple’s September iPhone Launch Tests Its New Era of Growth

Apple’s decision to hold its next major iPhone event on September 9 comes at a strategically important moment for the company. The date follows Apple’s traditional September product cycle, but this year the event carries significance beyond the annual smartphone refresh. It will be the first major...

Nvidia’s Rubin Chip Transition Faces a Tougher Growth Test

Nvidia enters its next stage of artificial intelligence growth with an unusually high burden of expectations. The company has become the biggest beneficiary of the global race to build AI infrastructure, but the conditions that produced its extraordinary expansion are now being tested. Its Vera...

Shein’s Valuation Reset Exposes the Cost of Ultra-Fast Fashion

Shein’s decision to launch its long-awaited Hong Kong initial public offering at a valuation of up to about $27 billion marks more than a steep reduction in the price investors are willing to place on the fast-fashion company. It signals a fundamental reassessment of the business model that once...

Melanoma Vaccine of Moderna Success Opens A New Path For Personalized Cancer Care

A personalized cancer vaccine developed by Moderna in partnership with Merck has produced positive results in a large late-stage trial for high-risk melanoma, providing further evidence that messenger RNA technology could have applications far beyond infectious diseases. The treatment, called...

Lilly's Retatrutide Related Lawsuits Expose Limits of Online Drug Enforcement

Eli Lilly's decision to file six lawsuits against companies accused of selling unauthorized versions of retatrutide represents a sharp escalation in the pharmaceutical industry's effort to control the market for experimental obesity treatments before they reach patients through legitimate channels....
1 2 3 4 5 » ... 274